Despite the presence of divergent data regarding the sporadic ineffectiveness of the suppression of STAT3 activity, it is imperative to acknowledge that strategies that disrupt STAT3 signalling can nevertheless elicit substantial antitumour effects by modulating the tumour microenvironment. The gene discussed is STAT3; the disease is neoplasm.